Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 20;47(2):618–629. doi: 10.1007/s00261-021-03331-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Resolution of the discordant appearance of intrazonal recurrence on MRI and CEUS, after RFA in a 70-year-old man with HBV cirrhosis. a) Unenhanced T1 weighted fat suppressed (T1FS) image shows a mildly hypointense treatment site (white arrows) with curvilinear arrows of hyperintensity at the periphery of the treatment site. b) Arterial phase T1FS subtracted image shows a mildly hyperenhancing nodular focus (gray arrow), within the anterior aspect of the treatment site (white arrows). c) Delayed phase T1FS subtracted image shows persistent enhancement (gray arrow) of the mildly arterially hyperenhancing focus, with no convincing evidence of washout. d) Gray-scale US image shows a mildly hyperechoic treatment site (white arrows). e) CEUS image obtained 30 seconds after microbubble contrast injection shows a nodular area of hyperenhancement (gray arrow) in the anterior aspect of an otherwise avascular treatment site (white arrows), corresponding to the mildly arterially hyperenhancing focus seen on the MRI. f) CEUS image obtained at 3 minutes shows washout of the arterially hyperenhancing nodular focus, in keeping with washout, leaving a completely avascular treatment site (white arrows)